We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+31.13%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$4.73B
AUM Growth
+$575M
(+14%)
Cap. Flow
-$244M
Cap. Flow
% of AUM
-5.15%
Top 10 Holdings %
Top 10 Hldgs %
46.08%
Holding
127
New
17
Increased
23
Reduced
25
Closed
19
Avg Time Held Equity + Options
7.6
quarters
Top 10 Avg Time Held Equity + Options
6.2
quarters
Top 20 Avg Time Held Equity + Options
5.8
quarters
Avg Time Held Equity only
8
quarters
Top 10 Avg Time Held Equity only
6.2
quarters
Top 20 Avg Time Held Equity only
5.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VRNA
Verona Pharma
VRNA
|
+$95.5M |
| 2 |
Viking Therapeutics
VKTX
|
+$57.4M |
| 3 |
argenx
ARGX
|
+$52.2M |
| 4 |
Adagio Medical Holdings
ADGM
|
+$46.7M |
| 5 |
Oruka Therapeutics
ORKA
|
+$43M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
+$441M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$74.1M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$60M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
+$38.8M |
| 5 |
SpringWorks Therapeutics
SWTX
|
+$35.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.6% |
| 2 | Miscellaneous | 1.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Orchestra BioMed
OBIO
$346M
| $23.6M | 0.5% |
4,592,556
+2,046,675
| +80% | +$13.4M |
2023 Q1
6 quarters
|
|
52
Instil Bio
TIL
$41.4M
| $23.3M | 0.49% |
+345,545
| New | +$8.14M |
2024 Q3
0 quarters
|
|
53
LivaNova
LIVN
$4.19B
| $22.5M | 0.48% |
429,000
-15,000
| -3% | -$744K |
2024 Q1
2 quarters
|
|
|
54
DELISTED
SpringWorks Therapeutics
SWTX
| $22.2M | 0.47% |
692,263
-960,699
| -58% | -$35.9M |
2019 Q3
20 quarters
|
|
55
Medtronic
MDT
$119B
| $22.1M | 0.47% |
245,332
-245,333
| -50% | -$20.6M |
2023 Q2
5 quarters
|
|
56
ADMA Biologics
ADMA
$2.37B
| $21.2M | 0.45% |
1,060,200
-1,710,800
| -62% | -$26.6M |
2016 Q3
32 quarters
|
|
57
Xenon Pharmaceuticals
XENE
$3.3B
| $20.7M | 0.44% |
524,930
-58,326
| -10% | -$2.35M |
2021 Q1
14 quarters
|
|
58
Zenas BioPharma
ZBIO
$1.62B
| $19.4M | 0.41% |
+1,144,035
| New | +$20.6M |
2024 Q3
0 quarters
|
|
59
Disc Medicine
IRON
$2.18B
| $19M | 0.4% |
387,017
-166,420
| -30% | -$7.81M |
2023 Q2
5 quarters
|
|
60
Rocket Pharmaceuticals
RCKT
$245M
| $17.2M | 0.36% |
931,851
-314,746
| -25% | -$6.45M |
2018 Q4
23 quarters
|
|
61
Inhibrx
INBX
$1.25B
| $16.7M | 0.35% |
1,064,026
| – | – |
2024 Q2
1 quarter
|
|
62
Rapport Therapeutics
RAPP
$1.37B
| $15.3M | 0.32% |
748,183
| – | – |
2024 Q2
1 quarter
|
|
63
DELISTED
Merus
MRUS
| $15M | 0.32% |
300,000
| – | – |
2024 Q2
1 quarter
|
|
64
Insmed
INSM
$21.3B
| $13.1M | 0.28% |
180,000
| – | – |
2024 Q2
1 quarter
|
|
65
Icon
ICLR
$13B
| $12.7M | 0.27% |
44,353
+13,103
| +42% | +$4.13M |
2024 Q2
1 quarter
|
|
66
Arcutis Biotherapeutics
ARQT
$3.36B
| $12.6M | 0.27% |
1,358,500
-200,000
| -13% | -$1.97M |
2024 Q1
2 quarters
|
|
67
PepGen
PEPG
$161M
| $12.1M | 0.26% |
1,410,438
| – | – |
2024 Q1
2 quarters
|
|
68
Tyra Biosciences
TYRA
$1.26B
| $12M | 0.25% |
511,226
-496,141
| -49% | -$10.4M |
2021 Q3
12 quarters
|
|
69
Xencor
XNCR
$1.75B
| $10.6M | 0.22% |
+527,671
| New | +$9.91M |
2024 Q3
0 quarters
|
|
70
Verrica Pharmaceuticals
VRCA
$64.8M
| $10.3M | 0.22% |
709,918
| – | – |
2018 Q2
25 quarters
|
|
71
Roivant Sciences
ROIV
$24.4B
| $9.78M | 0.21% |
+847,745
| New | +$9.65M |
2024 Q3
0 quarters
|
|
72
ArriVent BioPharma
AVBP
$759M
| $9.75M | 0.21% |
415,000
| – | – |
2024 Q1
2 quarters
|
|
73
DELISTED
Exact Sciences
EXAS
| $8.52M | 0.18% |
+125,000
| New | +$7.05M |
2024 Q3
0 quarters
|
|
74
EyePoint Inc
EYPT
$255M
| $8.29M | 0.18% |
1,037,274
+397,000
| +62% | +$3.49M |
2023 Q4
3 quarters
|
|
75
Allogene Therapeutics
ALLO
$432M
| $7.63M | 0.16% |
2,725,000
| – | – |
2024 Q2
1 quarter
|
|
Similar funds
QP
RWM
AWA
WHRC
KGA
LSERS
CAG
MCM
Perceptive Advisors's Q3 2024 Portfolio in Review
As of Q3 2024, Perceptive Advisors held 127 positions worth $4.73B, up 14% from $4.15B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Perceptive Advisors withdrew a net $244M in Q3 2024, closing 19 positions and reducing 25 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $441M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
Against the trend, Perceptive Advisors opened a new position in Adagio Medical Holdings worth $25.3M.
- Perceptive Advisors's largest Q3 2024 buy was Adagio Medical Holdings: 9,812,419 shares worth $25.3M.
- Perceptive Advisors added most to Verona Pharma in Q3 2024, an estimated $95.5M increase.
- Perceptive Advisors's biggest Q3 2024 reduction was Neurocrine Biosciences, cutting an estimated $60M.
- Perceptive Advisors fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $441M.
- Perceptive Advisors's ten largest holdings make up 46% of its $4.73B portfolio in Q3 2024.
- Perceptive Advisors opened 17 new positions and closed 19 in Q3 2024.
- Perceptive Advisors's portfolio value rose 14% quarter-over-quarter to $4.73B.
Based on Perceptive Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.